摘要
目的研究分析托法替布联合甲氨蝶呤(MTX)治疗类风湿性关节炎(RA)患者的临床效果。方法选择2023年6月至2024年6月期间在盐城市第一人民医院接受治疗的80例RA患者,采用随机数字法将其分为研究组和对照组,对照组采用每组40例。对比两组治疗效果、免疫指标、实验室指标及不良反应。结果研究组治疗总有效率较对照组高,P<0.05。治疗前,两组IgA、IgG、IgM、CD3+、CD4+、CD8+对比,P>0.05;治疗后,研究组IgA、IgG、IgM、CD3+、CD4+、CD8+均较对照组低,P<0.05。治疗前,两组血清CRP、RF水平及ESR对比,P>0.05;治疗后,研究组血清CRP、RF水平及ESR均较对照组低,P<0.05。两组不良反应发生率对比,P>0.05。结论托法替布联合MTX治疗RA患者可改善其免疫功能与实验室指标,提高治疗效果,且联合用药的安全性较高。
Objective:To study and analyze the clinical effect of tofacib combined with methotrexate(MTX)in the treatment of rheumatoid arthritis(RA).Methods:80 patients with RA who were treated in the First People's Hospital of Yancheng from June 2023 to June 2024 were randomly divided into study group and control group,with 40 patients in each group in the control group.The therapeutic effect、immune indexes、laboratory indexes and adverse reactions were compared between the two groups.Results:The total effective rate of the study group was higher than that of the control group,P<0.05.Before treatment,IgA、IgG、IgM、CD3+、CD4+and CD8+were compared between the two groups,P>0.05;After treatment,IgA、IgG、IgM、CD3+、CD4+and CD8+in the study group were lower than those in the control group,P<0.05.Before treatment,the levels of serum CRP、RF and ESR were compared between the two groups,P>0.05.After treatment,the levels of serum CRP、RF and ESR in the study group were lower than those in the control group,P<0.05.The incidence of adverse reactions between the two groups was compared,P>0.05.Conclusion:Tofatib combined with MTX can improve the immune function and laboratory indexes of RA patients,and improve the therapeutic effect,and the safety of combined medication is high.
作者
卞月存
周芳芳
Bian Yuecun;Zhou Fangfang(Yancheng First People's Hospital,Yancheng Jiangsu 224000,China)
出处
《生命科学仪器》
2024年第4期129-131,共3页
Life Science Instruments
